The EpiPen, a life-saving medication for individuals suffering from severe allergies, has seen its price rise dramatically from $100 in 2007 to over $600 in 2016. Amidst public backlash and inquiries from Congress, pharmaceutical companies Pfizer, Mylan, and Teva have agreed to a $123.5 million settlement over allegations of anticompetitive practices. The lawsuit claims the companies illegally delayed the launch of a generic EpiPen, thereby extending Pfizer and Mylan's monopoly over the epinephrine autoinjector drug market and extracting more profits from American consumers and insurers. This class action lawsuit specifically targets direct purchasers of EpiPen, including entities and individuals who purchased the EpiPen or its generic form directly from Mylan or Teva for resale purposes. This case exemplifies the ongoing debate over drug pricing in the United States, highlighting the potential for anticompetitive practices in the pharmaceutical industry. While this lawsuit provides some compensation to direct purchasers, the high cost of EpiPen remains a challenge for cash-paying or underinsured individuals. Separate class actions exist for consumers who purchase through retail channels, displaying the broad impact of these alleged price-fixing practices.